Lauren Haley
Family · Fayette, ALNPI 1114423936
Payments from drug & device makers
Across 119 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$322
- Amgen$290
- AstraZeneca$286
- Lilly USA, LLC$206
- Otsuka America Pharmaceutical, Inc.$196
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$191
- plus $713 from 14 others
What the payments were for
- Food & beverage$2,205100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $322 |
| Amgen | 16 | $290 |
| AstraZeneca | 15 | $286 |
| Lilly USA, LLC | 11 | $206 |
| Otsuka America Pharmaceutical, Inc. | 8 | $196 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $191 |
| Neurocrine Biosciences, Inc. | 7 | $133 |
| Pfizer | 7 | $118 |
| Atland Pharmaceuticals, LLC | 1 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Dexcom, Inc. | 3 | $67 |
| Lundbeck LLC | 2 | $45 |
| Exact Sciences | 2 | $35 |
| Abbott | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| GSK | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Bayer | 1 | $17 |
How this compares
$2,205 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $41,867 |
| MounjaroTirzepatide | 18 | $18,600 |
| EliquisApixaban | 19 | $12,856 |
| VascepaIcosapent Ethyl | 27 | $12,400 |
| NovologInsulin Aspart | 15 | $4,196 |
| SynthroidLevothyroxine Sodium | 21 | $1,635 |
| Celecoxib | 32 | $1,252 |
| Levothyroxine Sodium | 135 | $1,247 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,207 |
| Buspirone Hcl | 80 | $1,205 |
| Diclofenac Sodium | 30 | $1,151 |
| Colesevelam Hcl | 12 | $1,009 |
| Omeprazole | 73 | $886 |
| Rosuvastatin Calcium | 38 | $865 |
| Duloxetine Hcl | 29 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $322 | $46,06359 claims |
| Lilly USA, LLCMounjaro | $206 | $18,60018 claims |
| PfizerEliquis | $118 | $12,85619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.
Other family in Fayette
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.